Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USP32 small interfering RNA (siRNA) is an experimental RNA interference (RNAi) agent designed to silence the expression of the ubiquitin-specific peptidase 32 (USP32) gene. USP32 is a deubiquitinating enzyme that is frequently overexpressed in various malignancies, including non-small cell lung cancer (NSCLC), where it correlates with poor prognosis. By targeting USP32 mRNA for degradation, the siRNA reduces USP32 protein levels, which subsequently leads to the destabilization of its substrates, such as Bcl2-associated athanogene 3 (BAG3). The downregulation of the USP32-BAG3 axis results in the inhibition of the RAF-MEK-ERK signaling pathway, thereby suppressing tumor cell proliferation, migration, and epithelial-mesenchymal transition (EMT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on USP32 small interfering RNA.